Arkema (AKE.PA): Buying a Chemical Cycle Inflection That Nobody Believes In #

22 May 2026 | Price: EUR 62.20 | Position: 10 shares @ EUR 62.25 | Total cost: EUR 627.40

The set-up in one paragraph #

Arkema is a EUR 4.7B French specialty chemicals company trading at 0.76x book value and a 5.8% dividend yield. The chemicals cycle troughed in Q4 2025 (EBITDA collapsed to EUR 74M), and Q1 2026 showed the first snap-back to EUR 283M. The stock barely moved on the news because sell-side analysts — correctly — flagged that roughly half of that snap-back came from a temporary Hormuz-driven spike in acrylic acid prices, not from genuine demand recovery. The investment question is whether the other half of the recovery (adhesives, coatings, advanced materials) is real and durable. If yes, the stock is dramatically cheap at 10.5x forward earnings. If no, you're buying a 5.8% dividend yield and waiting, with downside to EUR 50-55. We bought 10 shares on Monday at EUR 62.25. Today JPMorgan downgraded the stock to Underweight with a EUR 50 target. So let's walk through both sides of this trade honestly.

Part 1: The Bull Case #

1. The valuation is extreme — if earnings are real #

At EUR 62.20, Arkema trades at:

This isn't a "slightly cheap" stock. It's priced for a scenario where earnings don't recover. The market is applying recession multiples to a company that just printed a +283% sequential EBITDA improvement.

2. The Q1 inflection was real — even stripping out Hormuz #

Q1 2026 EBITDA of EUR 283M wasn't entirely a geopolitical fluke. The Intermediates segment (acrylics) got a windfall from disrupted Gulf shipping, yes. But Bostik adhesives, Coating Solutions, and Advanced Materials all showed sequential improvement. These are customer-driven businesses: when your customers' warehouses are empty after 18 months of destocking, they start ordering again. That's the boring, durable part of the recovery.

Management guided Q2 EBITDA "comparable to Q2 2025" (~EUR 276M) and full-year "slight EBITDA growth at constant FX." They're not promising a boom. They're saying the trough is behind us.

3. There's a growth story that isn't being priced #

New capacity coming online H2 2026:

• PVDF plant in the US — produces binders for EV battery electrodes. Capex already spent. A typical EV uses ~$1,500 of specialty chemicals vs ~$400 for an ICE car. Even if total auto production is flat, the mix shift toward EVs increases Arkema's revenue-per-vehicle by 3-4x.
• PA11 plant in Singapore — bio-based polymers from castor oil. High-margin specialty, growing demand in sports equipment, electronics, and medical.

These aren't speculative R&D projects. The capex is sunk. They either ramp and contribute, or they don't — and there's no evidence they won't.

4. The asset floor is real #

Book value per share is EUR 81.37. At EUR 62.20, you're buying at a 24% discount to book. For a specialty chemicals company with real plants, real inventory, and real receivables — not a bank with opaque Level 3 assets — that's unusual.

Berenberg's own sum-of-the-parts analysis (they're bears!) implies EUR 62/share. They explicitly note that a sale of the adhesives unit at 8-9x EBITDA would unlock "over EUR 70/share of value." The bear case from the bears still gets you to roughly the current price.

5. You get paid 5.8% to wait #

EUR 3.60/share annual dividend. Over 3 years, that's roughly EUR 10.80 in dividends — a 17% cumulative return on the entry price even if the stock goes nowhere. In the bear case (stock drifting to EUR 50-55), dividends largely offset the capital loss. In the base case (stock to EUR 72-75), dividends add to a ~28% total return. In the bull case, the dividend is gravy on a 75%+ gain.

6. The sell-side isn't uniformly bearish #

8 of 16 analysts still rate it Buy. The mean target is EUR 63.88 — essentially at the current price. Morgan Stanley (Buy, EUR 83 target) sees the recovery thesis. The bears (JPMorgan EUR 50, Barclays EUR 47) are in the minority — vocal, but minority.

Part 2: The Bear Case #

This section deserves equal weight. The bears have specific, testable arguments, not vague skepticism.

1. The Q1 beat was a Hormuz mirage #

This is Berenberg's core argument, and JPMorgan echoed it today. The chain:

• Iran/Hormuz disruption → Gulf propylene can't reach global markets → competitors who depend on Gulf feedstock can't produce → acrylic acid prices spike from $200-300/t to $900/t → Arkema's Intermediates segment prints a windfall
• When Hormuz normalizes (Baker Hughes estimate: H2 2026), the chain reverses. Acrylic spreads collapse. EUR ~100M of annual EBITDA disappears.
• Berenberg's ChemCast model puts 2027 consensus EBITDA at EUR 1.23B vs the EUR 1.37B consensus — a 10.3% gap. If Berenberg is right, 2027 forward P/E isn't 10.5x, it's closer to 12-13x. Still not expensive, but less compelling.

JPMorgan's downgrade today was explicit: "Middle East conflict tailwinds fading faster than expected" and "significant consensus earnings cuts for H2 2026 and FY 2027."

2. The analyst trend is deteriorating #

Since Q1 earnings on May 6:

That's 4 downgrades vs 1 upgrade in two weeks. The momentum in analyst sentiment is clearly negative.

3. The macro is genuinely hostile #

• European construction remains soft — Bostik's biggest end-market
• Chinese overcapacity in acrylic acid and commodity chemicals is structural, not cyclical
• EV adoption slowing — Tesla margin compression, Northvolt bankruptcy (a real Arkema customer)
• Trade tensions — US-EU and US-China tariffs add uncertainty to a global supply chain business
• Revenue was down -8.4% YoY in Q1. That's not a growth story yet.

4. No insider conviction #

Zero insider transactions in the last 6 months. No CEO buying. No CFO buying. No board buying. For a stock supposedly at a 24% discount to book value with a cyclical recovery underway, the people who know the business best aren't putting their own money in. Per shr-002, this is a missing confirming signal — not a red flag by itself — but it's a data point the bears can point to.

5. The ex-dividend mechanical headwind #

The stock goes ex-div on Monday May 25. It will open approximately EUR 3.60 lower at ~EUR 58.60. That's an immediate -5.9% mark-to-market paper loss on our EUR 62.25 entry. The dividend payment on May 27 offsets this economically, but psychologically and optically, the position will show red from day 7.

From a post-div EUR 58.60, the distance to JPMorgan's EUR 50 target is 14.7%. If analyst downgrades continue and the macro doesn't improve, that path is plausible.

6. Capex consumes the free cash flow #

EUR 600M annual capex against a EUR 4.7B market cap. That's 12.8% of market cap being reinvested every year, mostly into growth projects (PVDF, PA11) whose returns aren't yet visible. If those projects disappoint, FCF generation looks much less impressive. The bull case assumes capex normalizes after 2026 — bears argue it's structural.

Part 3: What We Actually Did #

On Monday May 18, we bought 10 shares at EUR 62.25 (filled at the opening auction, EUR 0.75 below our EUR 63 limit). Total cost: EUR 627.40 including EUR 4.90 DEGIRO fees.

Sizing rationale:

• The capital came from the EUR 660 value bucket (cash freed from exiting the SLS biotech position)
• 10 shares = 95% of the bucket deployed. For context, this is a satellite position within an 80/20 core-satellite framework (shr-019). At EUR 627, it represents roughly 1.5% of a EUR 40K total portfolio.
• We did not split T1 into 5+5. With only EUR 660 to deploy, splitting would have cut the dividend capture in half (EUR 18 instead of EUR 36) and left cash idle. The structural T2 comes from future monthly contributions, not from holding back T1 capital.

Tranche 2 plan — KILL conditions, not GO conditions:

This is the key structural innovation. Instead of waiting for positive confirmation to deploy T2 (which paralysed our RI.PA position for 10+ months), T2 is the default action when the stock hits EUR 52. The only question is: has the thesis broken?

If none of these have triggered when the stock hits EUR 52, we buy. No waiting for the chart to look good. No waiting for analyst upgrades. The drop is the buy signal.

Exit targets (tiered, per shr-016):

Fundamental stops (no price-based stops):

• Dividend cut → EXIT
• Net debt/EBITDA > 5x → EXIT
• CEO departure → RE-SCORE within 5 days
• Two consecutive quarterly misses → RE-SCORE

Part 4: The Key Question — Inflection or Mirage? #

The entire thesis reduces to one question: Was Q4 2025 the trough of the chemicals cycle?

If yes: the forward P/E of 10.5x is real, the recovery compounds through 2027-28, and the stock re-rates to 12-14x earnings. You make 40-75% over 3 years while collecting a 5.8% dividend.

If no: Q4 2025 wasn't the trough, Q1 2026 was a head-fake driven by geopolitics, and the stock drifts to EUR 50-55. You collect ~17% in dividends over 3 years and end roughly flat.

The asymmetry is the point. In the bull case, you make 75%. In the bear case, you make ~0% (dividends offset capital loss). There is no scenario where Arkema at 0.76x book and 10.5x forward earnings is expensive. It's either cheap or fairly valued. That's the margin of safety.

The JPMorgan downgrade today doesn't change this. It increases the probability of the bear case (the stock getting closer to our EUR 52 T2 trigger), but it doesn't break the thesis. JPMorgan is making a call about the speed of Hormuz normalization and the timing of consensus estimate cuts — not about Arkema being a fundamentally broken business. Their EUR 50 target is a 12-month price target, not a liquidation value.

Part 5: What Would Prove Us Wrong? #

Honesty about kill conditions is the difference between an investment thesis and a narrative you tell yourself. Here's what would break this:

1. Q2 2026 EBITDA below EUR 200M (late July). If the sequential recovery reverses, the "trough is behind us" thesis is wrong. This is the single most important data point.
2. Dividend cut. The 5.8% yield is the downside cushion. If it's cut, the income pillar of the thesis breaks.
3. Le Hénaff departure. After 20 years, if he leaves during a cyclical trough, it's likely not voluntary.
4. Bostik impairment. This would mean the 2015 acquisition that defines Arkema's specialty transition is worth less than the balance sheet says.

Notice what's not on the kill list: stock price, analyst downgrades, Hormuz reopening, or quarterly volatility. Those are noise. The signal is whether the underlying business is recovering or deteriorating.

Part 6: The Verdict #

This is a good investment at EUR 62.25, with the position size we've taken.

The case rests on three things that don't require genius to see:

1. Assets: You're paying 76 cents for a euro of book value in a business with real physical assets.
2. Income: You're being paid 5.8% annually to wait for the cycle to turn.
3. Inflection: Q1 showed the first signs of recovery across multiple segments, not just the Hormuz windfall.

The bears are right about one thing: the Hormuz bonus will fade, and when it does, headlines will be negative and analyst targets will come down. But the thesis was built on normalized spreads, not the windfall. The house metaphor from our research is correct — Hormuz is the chandelier. Beautiful when lit, but the walls (cyclical recovery, battery materials) and foundation (assets, dividend) do the structural work.

The JPMorgan downgrade today is uncomfortable. It would be easier to buy this stock when all 16 analysts rate it Buy and the macro is clear. But that trade doesn't exist — by the time everyone agrees the cycle has turned, the stock is at EUR 80 and the opportunity is gone. Graham's framework is explicitly about buying when the narrative is negative and the numbers say otherwise.

Conviction level: 7/10.

This is not a "back up the truck" 10/10. The macro headwinds are real (construction, China, trade), the analyst trend is deteriorating, and the Hormuz windfall creates genuine uncertainty about the quality of Q1 earnings. This is a "starter position with a clear T2 plan at lower prices" investment — exactly what we've done.

If the stock goes to EUR 52 without a kill condition triggering, we add. If it goes to EUR 72, we trim. If it goes to EUR 110, we exit. The framework handles all three paths. The one thing we won't do is sell at EUR 58 because JPMorgan said so.

Monitoring Calendar #

Position: Long AKE.PA. 10 shares at EUR 62.25. Not investment advice. This is a personal portfolio analysis. See execution log and thesis for full details.